Role of polyethylene particles in peri-prosthetic osteolysis: A review

World Journal of Orthopedics

Volumn 2, Issue 10, 2011, Pages 93-101

  Atkins, Gerald J ^a   Haynes, David R ^a   Howie, Donald W ^a   Findlay, David M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Aseptic loosening; Osteolysis; Peri prosthetic; Polyethylene; Wear particle

Indexed keywords

EID: 84863194792     PISSN: None     EISSN: 22185836     Source Type: Journal    
DOI: 10.5312/wjo.v2.i10.93     Document Type: Review

References (94)

1. Harris WH, Schiller AL, Scholler JM, Freiberg RA, Scott R. Extensive localized bone resorption in the femur following total hip replacement. J Bone Joint Surg Am 1976; 58: 612-618.
2. Wang ML, Sharkey PF, Tuan RS. Particle bioreactivity and wear-mediated osteolysis. J Arthroplasty 2004; 19: 1028-1038.
3. Total hip replacement. NIH Consens Statement 1994; 12: 1-31.
4. Skoglund B, Holmertz J, Aspenberg P. Systemic and local ibandronate enhance screw fixation. J Orthop Res 2004; 22: 1108-1113.
5. McEvoy A, Jeyam M, Ferrier G, Evans CE, Andrew JG. Synergistic effect of particles and cyclic pressure on cytokine production in human monocyte/macrophages: proposed role in periprosthetic osteolysis. Bone 2002; 30: 171-177.
6. Haynes DR, Rogers SD, Hay S, Pearcy MJ, Howie DW. The differences in toxicity and release of bone-resorbing mediators induced by titanium and cobalt-chromium-alloy wear particles. J Bone Joint Surg Am 1993; 75: 825-834.
7. Kaufman AM, Alabre CI, Rubash HE, Shanbhag AS. Human macrophage response to UHMWPE, TiAlV, CoCr, and alumina particles: analysis of multiple cytokines using protein arrays. J Biomed Mater Res A 2008; 84: 464-474.
8. Jones LC, Frondoza C, Hungerford DS. Effect of PMMA particles and movement on an implant interface in a canine model. J Bone Joint Surg Br 2001; 83: 448-458.
9. Revell PA, Weightman B, Freeman MA, Roberts BV. The production and biology of polyethylene wear debris. Arch Orthop Trauma Surg 1978; 91: 167-181.
10. Looney RJ, Boyd A, Totterman S, Seo GS, Tamez-Pena J, Campbell D, Novotny L, Olcott C, Martell J, Hayes FA, Ó Keefe RJ, Schwarz EM. Volumetric computerized tomography as a measurement of periprosthetic acetabular osteolysis and its correlation with wear. Arthritis Res 2002; 4: 59-63.
11. Kim KJ, Kobayashi Y, Itoh T. Osteolysis model with continuous infusion of polyethylene particles. Clin Orthop Relat Res 1998; 46-52.
12. Howie DW, Neale SD, Stamenkov R, McGee MA, Taylor DJ, Findlay DM. Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. J Bone Joint Surg Am 2007; 89: 1818-1825.
13. Gupta SK, Chu A, Ranawat AS, Slamin J, Ranawat CS. Osteolysis after total knee arthroplasty. J Arthroplasty 2007; 22: 787-799.
14. Ingram RT, Bonde SK, Riggs BL, Fitzpatrick LA. Effects of transforming growth factor beta (TGF beta) and 1,25 dihydroxyvitamin D3 on the function, cytochemistry and morphology of normal human osteoblast-like cells. Differentiation 1994; 55: 153-163.
15. Matthews JB, Besong AA, Green TR, Stone MH, Wroblewski BM, Fisher J, Ingham E. Evaluation of the response of primary human peripheral blood mononuclear phagocytes to challenge with in vitro generated clinically relevant UHMWPE particles of known size and dose. J Biomed Mater Res 2000; 52: 296-307.
16. Sieving A, Wu B, Mayton L, Nasser S, Wooley PH. Morphological characteristics of total joint arthroplasty-derived ultra-high molecular weight polyethylene (UHMWPE) wear debris that provoke inflammation in a murine model of inflammation. J Biomed Mater Res A 2003; 64: 457-464.
17. Gomez-Barrena E, Puertolas JA, Munuera L, Konttinen YT. Update on UHMWPE research: from the bench to the bedside. Acta Orthop 2008; 79: 832-840.
18. Glyn-Jones S, Isaac S, Hauptfleisch J, McLardy-Smith P, Murray DW, Gill HS. Does highly cross-linked polyethylene wear less than conventional polyethylene in total hip arthroplasty? A double-blind, randomized, and controlled trial using roentgen stereophotogrammetric analysis. J Arthroplasty 2008; 23: 337-343.
19. Thomas GER, Simpson DJ, Mehmood S, Taylor A, McLardy-Smith P, Gill HS, Murray DW, Glyn-Jones S. The seven-year wear of highly cross-linked polyethylene in total hip arthroplasty: a double-blind, randomized controlled trial using radiostereometric analysis. J Bone Joint Surg Am 2011;93:716-22.
20. Kurtz SM, Gawel HA, Patel JD. History and systematic review of wear and osteolysis outcomes for first-generation highly crosslinked polyethylene. Clin Orthop Relat Res 2011; 469: 2262-2277.
21. Engh CA, Stepniewski AS, Ginn SD, Beykirch SE, Sychterz-Terefenko CJ, Hopper RH, Engh CA. A randomized prospective evaluation of outcomes after total hip arthroplasty using cross-linked marathon and non-cross-linked Enduron polyethylene liners. J Arthroplasty 2006; 21: 17-25.
22. Leung SB, Egawa H, Stepniewski A, Beykirch S, Engh CA, Engh CA. Incidence and volume of pelvic osteolysis at early follow-up with highly cross-linked and noncross-linked polyethylene. J Arthroplasty 2007; 22: 134-139.
23. Mall NA, Nunley RM, Zhu JJ, Maloney WJ, Barrack RL, Clohisy JC. The incidence of acetabular osteolysis in young patients with conventional versus highly crosslinked polyethylene. Clin Orthop Relat Res 2011; 469: 372-381.
24. Schroder DT, Kelly NH, Wright TM, Parks ML. Retrieved highly crosslinked UHMWPE acetabular liners have similar wear damage as conventional UHMWPE. Clin Orthop Relat Res 2011; 469: 387-394.
25. Endo M, Tipper JL, Barton DC, Stone MH, Ingham E, Fisher J. Comparison of wear, wear debris and functional biological activity of moderately crosslinked and non-crosslinked polyethylenes in hip prostheses. Proc Inst Mech Eng H 2002; 216: 111-122.
26. Illgen RL, Forsythe TM, Pike JW, Laurent MP, Blanchard CR. Highly crosslinked vs conventional polyethylene particles-an in vitro comparison of biologic activities. J Arthroplasty 2008; 23: 721-731.
27. Bi Y, Seabold JM, Kaar SG, Ragab AA, Goldberg VM, Anderson JM, Greenfield EM. Adherent endotoxin on orthopedic wear particles stimulates cytokine production and osteoclast differentiation. J Bone Miner Res 2001; 16: 2082-2091.
28. Takagi M. Bone-implant interface biology: foreign body reaction and periprosthetic osteolysis in artificial hip joints. J Clin Exp Hematopathol 2001; 41: 81-87.
29. Takagi M, Santavirta S, Ida H, Ishii M, Takei I, Niissalo S, Ogino T, Konttinen YT. High-turnover periprosthetic bone remodeling and immature bone formation around loose cemented total hip joints. J Bone Miner Res 2001; 16: 79-88.
30. Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ, Glant TT. Osteolysis: basic science. Clin Orthop Relat Res 2001; 71-77.
31. Haynes DR, Crotti TN, Zreiqat H. Regulation of osteoclast activity in peri-implant tissues. Biomaterials 2004; 25: 4877-4885.
32. Goodman SB, Lind M, Song Y, Smith RL. In vitro, in vivo, and tissue retrieval studies on particulate debris. Clin Orthop Relat Res 1998; 25-34.
33. McGee MA, Howie DW, Neale SD, Haynes DR, Pearcy MJ. The role of polyethylene wear in joint replacement failure. Proc Inst Mech Eng H 1997; 211: 65-72.
34. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 2004; 25: 565-573.
35. Kobayashi A, Freeman MA, Bonfield W, Kadoya Y, Yamac T, Al-Saffar N, Scott G, Revell PA. Number of polyethylene particles and osteolysis in total joint replacements. A quantitative study using a tissue-digestion method. J Bone Joint Surg Br 1997; 79: 844-848.
36. Takagi M, Santavirta S, Ida H, Ishii M, Akimoto K, Saotome K, Konttinen YT. The membrane-type-matrix metalloproteinase/matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 system in periprosthetic connective-tissue remodeling in loose total-hip prostheses. Lab Invest 1998; 78: 735-742.
37. Takagi M, Santavirta S, Ida H, Ishii M, Mandelin J, Konttinen YT. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in loose artificial hip joints. Clin Orthop Relat Res 1998; 35-45.
38. Konttinen YT, Takagi M, Mandelin J, Lassus J, Salo J, Ainola M, Li TF, Virtanen I, Liljestrom M, Sakai H, Kobayashi Y, Sorsa T, Lappalainen R, Demulder A, Santavirta S. Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. J Bone Miner Res 2001; 16: 1780-1786.
39. Goodman SB, Huie P, Song Y, Schurman D, Maloney W, Woolson S, Sibley R. Cellular profile and cytokine production at prosthetic interfaces. Study of tissues retrieved from revised hip and knee replacements. J Bone Joint Surg Br 1998; 80: 531-539.
40. Holding CA, Findlay DM, Stamenkov R, Neale SD, Lucas H, Dharmapatni AS, Callary SA, Shrestha KR, Atkins GJ, Howie DW, Haynes DR. The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 2006; 27: 5212-5219.
41. Al Saffar N, Revell PA. Interleukin-1 production by activated macrophages surrounding loosened orthopaedic implants: a potential role in osteolysis. Br J Rheumatol 1994; 33: 309-316.
42. Takei I, Takagi M, Ida H, Ogino T, Santavirta S, Konttinen YT. High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints. J Rheumatol 2000; 27: 894-899.
43. Nakashima Y, Sun DH, Trindade MC, Chun LE, Song Y, Goodman SB, Schurman DJ, Maloney WJ, Smith RL. Induction of macrophage C-C chemokine expression by titanium alloy and bone cement particles. J Bone Joint Surg Br 1999; 81: 155-162.
44. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007; 40: 251-264.
45. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-1488.
46. Ma T, Huang Z, Ren PG, McCally R, Lindsey D, Smith RL, Goodman SB. An in vivo murine model of continuous intramedullary infusion of polyethylene particles. Biomaterials 2008; 29: 3738-3742.
47. Ingham E, Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials 2005; 26: 1271-1286.
48. Ren PG, Huang Z, Ma T, Biswal S, Smith RL, Goodman SB. Surveillance of systemic trafficking of macrophages induced by UHMWPE particles in nude mice by noninvasive imaging. J Biomed Mater Res A 2010; 94: 706-711.
49. Horowitz SM, Gonzales JB. Effects of polyethylene on macrophages. J Orthop Res 1997; 15: 50-56.
50. Ren W, Markel DC, Schwendener R, Ding Y, Wu B, Wooley PH. Macrophage depletion diminishes implant-wearinduced inflammatory osteolysis in a mouse model. J Biomed Mater Res A 2008; 85: 1043-1051.
51. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, Findlay DM. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br 2001; 83: 902-911.
52. Neale SD, Fujikawa Y, Sabokbar A, Gundle R, Murray DW, Graves SE, Howie DW, Athanasou NA. Human bonederived cells support formation of human osteoclasts from arthroplasty-derived cells in vitro. J Bone Joint Surg Br 2000; 82: 892-900.
53. Sabokbar A, Kudo O, Athanasou NA. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J Orthop Res 2003; 21: 73-80.
54. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-3602.
55. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2-12.
56. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NFkappa B ligand and support osteoclast differentiation. J Bone Miner Res 2000; 15: 1459-1466.
57. Mandelin J, Li TF, Hukkanen M, Liljeström M, Salo J, Santavirta S, Konttinen YT. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. J Rheumatol 2005; 32: 713-720.
58. Atkins GJ, Welldon KJ, Holding CA, Haynes DR, Howie DW, Findlay DM. The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials 2009; 30: 3672-3681.
59. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999; 265: 144-150.
60. Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, Ahern MJ, Haynes D. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003; 38: 380-387.
61. Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, Tak PP, Haynes DR. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002; 61: 1047-1054.
62. Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, Zannetino A, Ahern MJ, Coleman M, Roberts-Thomson PJ, Kraan M, Tak PP, Smith MD. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 2003; 42: 123-134.
63. Masui T, Sakano S, Hasegawa Y, Warashina H, Ishiguro N. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. Biomaterials 2005; 26: 1695-1702.
64. Findlay DM, Haynes DR. Mechanisms of bone loss in rheumatoid arthritis. Mod Rheumatol 2005; 15: 232-240.
65. Vincent C, Kogawa M, Findlay DM, Atkins GJ. The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions. J Bone Miner Metab 2009; 27: 114-119.
66. Goodman SB, Ma T. Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials 2010; 31: 5045-5050.
67. Gallo J, Raska M, Mrázek F, Petrek M. Bone remodeling, particle disease and individual susceptibility to periprosthetic osteolysis. Physiol Res 2008; 57: 339-349.
68. Martínez ME, Medina S, del Campo MT, García JA, Rodrigo A, Munuera L. Effect of polyethylene particles on human osteoblastic cell growth. Biomaterials; 19: 183-187.
69. Dean DD, Schwartz Z, Liu Y, Blanchard CR, Agrawal CM, Mabrey JD, Sylvia VL, Lohmann CH, Boyan BD. The effect of ultra-high molecular weight polyethylene wear debris on MG63 osteosarcoma cells in vitro. J Bone Joint Surg Am 1999; 81: 452-461.
70. Chiu R, Ma T, Smith RL, Goodman SB. Ultrahigh molecular weight polyethylene wear debris inhibits osteoprogenitor proliferation and differentiation in vitro. J Biomed Mater Res A 2009; 89: 242-247.
71. Vermes C, Chandrasekaran R, Jacobs JJ, Galante JO, Roebuck KA, Glant TT. The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Joint Surg Am 2001; 83-A: 201-211.
72. Rodrigo AM, Martinez ME, Saldaña L, Vallés G, Martinez P, González-Carrasco JL, Cordero J, Munuera L. Effects of polyethylene and alpha-alumina particles on IL-6 expression and secretion in primary cultures of human osteoblastic cells. Biomaterials 2002; 23: 901-908.
73. Granchi D, Ciapetti G, Amato I, Pagani S, Cenni E, Savarino L, Avnet S, Peris JL, Pellacani A, Baldini N, Giunti A. The influence of alumina and ultra-high molecular weight polyethylene particles on osteoblast-osteoclast cooperation. Biomaterials 2004; 25: 4037-4045.
74. Lohmann CH, Dean DD, Bonewald LF, Schwartz Z, Boyan BD. Nitric oxide and prostaglandin E2 production in response to ultra-high molecular weight polyethylene particles depends on osteoblast maturation state. J Bone Joint Surg Am 2002; 84-A: 411-419.
75. Atkins GJ, Welldon KJ, Wijenayaka AR, Bonewald LF, Findlay DM. Vitamin K promotes mineralization, osteoblastto-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and-independent mechanisms. Am J Physiol Cell Physiol 2009; 297: C1358-C1367.
76. Elfick AP, Green SM, McCaskie AW, Birch MA. Opsoniza-tion of polyethylene wear particles regulates macrophage and osteoblast responses in vitro. J Biomed Mater Res B Appl Biomater 2004; 71: 244-251.
77. Maitra R, Clement CC, Scharf B, Crisi GM, Chitta S, Paget D, Purdue PE, Cobelli N, Santambrogio L. Endosomal damage and TLR2 mediated inflammasome activation by alkane particles in the generation of aseptic osteolysis. Mol Immunol 2009; 47: 175-184.
78. Hao HN, Zheng B, Nasser S, Ren W, Latteier M, Wooley P, Morawa L. The roles of monocytic heat shock protein 60 and Toll-like receptors in the regional inflammation response to wear debris particles. J Biomed Mater Res A 2010; 92: 1373-1381.
79. Landesberg R, Eisig S, Fennoy I, Siris E. Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg 2009; 67: 27-34.
80. Millett PJ, Allen MJ, Bostrom MP. Effects of alendronate on particle-induced osteolysis in a rat model. J Bone Joint Surg Am 2002; 84-A: 236-249.
81. Shanbhag AS, Hasselman CT, Rubash HE. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop Relat Res 1997; 33-43.
82. Iwase M, Kim KJ, Kobayashi Y, Itoh M, Itoh T. A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyethylene particles. J Orthop Res 2002; 20: 499-505.
83. ÓHara LJ, Nivbrant B, Röhrl S. Cross-linked polyethylene and bisphosphonate therapy for osteolysis in total hip arthroplasty: a case report. J Orthop Surg (Hong Kong) 2004; 12: 114-121.
84. von Knoch F, Heckelei A, Wedemeyer C, Saxler G, Hilken G, Brankamp J, Sterner T, Landgraeber S, Henschke F, Löer F, von Knoch M. Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. J Biomed Mater Res A 2005; 75: 288-294.
85. Goater JJ, ÓKeefe RJ, Rosier RN, Puzas JE, Schwarz EM. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res 2002; 20: 169-173.
86. Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, ÓKeefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF-kappaB: Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 2002; 17: 192-199.
87. Goodman S, Trindade M, Ma T, Lee M, Wang N, Ikenou T, Matsuura I, Miyanishi K, Fox N, Regula D, Genovese M, Klein J, Bloch D, Smith RL. Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. J Biomed Mater Res A 2003; 65: 43-50.
88. Childs LM, Goater JJ, ÓKeefe RJ, Schwarz EM. Effect of anti-tumor necrosis factor-alpha gene therapy on wear debris-induced osteolysis. J Bone Joint Surg Am 2001; 83-A: 1789-1797.
89. Schwarz EM, Campbell D, Totterman S, Boyd A, ÓKeefe RJ, Looney RJ. Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. J Orthop Res 2003; 21: 1049-1055.
90. Dormán G, Cseh S, Hajdú I, Barna L, Kónya D, Kupai K, Kovács L, Ferdinandy P. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010; 70: 949-964.
91. Schwarz EM. What potential biologic treatments are available for osteolysis? J Am Acad Orthop Surg 2008; 16 Suppl 1: S72-S75.
92. Zhou X, Zhang P, Zhang C, Zhu Z. Promotion of bone formation by naringin in a titanium particle-induced diabetic murine calvarial osteolysis model. J Orthop Res 2010; 28: 451-456.
93. von Knoch F, Wedemeyer C, Heckelei A, Saxler G, Hilken G, Brankamp J, Sterner T, Landgraeber S, Henschke F, Löer F, von Knoch M. Promotion of bone formation by simvastatin in polyethylene particle-induced osteolysis. Biomaterials 2005; 26: 5783-5789.
94. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res 2010; 25: 1897-1904.